The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMateria Medica Holding
About this trial
Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial of the efficacy and safety of Raphamin in the treatment of acute rhinosinusitis in adult patients.
Eligibility criteria
Qualifiers
Male and female aged 18 - 75 years.
8-12 points on MSS scale;
no more than 3 severe symptoms (3 points on the MSS scale)
facial pain/heaviness in the facial area 1-2 points on the MSS scale.
Disqualifiers
fever of ≥ 38.0°C;
the second wave of ARS symptoms;
one-sided process;
facial pain/pressure of 3 points (on the MSS scale).
Trial design
Treatments tested in this trial
- Raphamin
- Placebo
Treatment groups
552 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov